June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Sustained release intravitreal dexamethazone implant in the treatment of proliferative diabetic retinopathy and diabetic macular edema
Author Affiliations & Notes
  • Angelo M Minnella
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • matteo federici
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • Giulia Maria Amorelli
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • gloria gambini
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • VALERIA PAGLIEI
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • MARIA CRISTINA SAVASTANO
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • Benedetto Falsini
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • aldo caporossi
    Institute of ophthalmology , Catholic University of Sacred Hearth, Rome, Italy
  • Footnotes
    Commercial Relationships   Angelo Minnella, None; matteo federici, None; Giulia Maria Amorelli, None; gloria gambini, None; VALERIA PAGLIEI, None; MARIA CRISTINA SAVASTANO, None; Benedetto Falsini, None; aldo caporossi, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 102. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Angelo M Minnella, matteo federici, Giulia Maria Amorelli, gloria gambini, VALERIA PAGLIEI, MARIA CRISTINA SAVASTANO, Benedetto Falsini, aldo caporossi; Sustained release intravitreal dexamethazone implant in the treatment of proliferative diabetic retinopathy and diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):102.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of intravitreal dexamethasone Implant (IDI) in reducing neovascularization in eyes affected by Proliferative Diabetic Retinopathy (PDR) using optical coherence tomography angiography (OCT-A) and fluorescein angiography (FA)

Methods : This interventional case series study included 8 eyes of 7 patients with PDR, affected by PDR and active new vessels (NV). All study eyes showed diabetic macular edema (central macular thickness >300 microns). A 700 micrograms slow release intravitreal dexamethasone implant (Ozurdex®) was injected in the vitreous cavity of study eyes. All eyes were evaluated with fluorescein angiography (FA) at baseline (T0) and T5 (3 months later). OCT angiography (OCTA) was performed at T0, T1 (6 hours), T2 (24 hours), T3 (1 week), T4 (1 month), T5 (3 months later, respectively). Quantitative planimetric analysis (QPA) of NV area was carried out before and after treatment with FA and OCTA

Results : Reduction in new vessels caliber was observed in all the study eyes leading to a reduction in the area of neovascularization. The reduction of the area carried to a significant upgrading in BCVA reported in all eyes at the end of the follow up

Conclusions : Intravitreal dexamethasone Implant (IDI) may be a suitable terapeutical option to Proliferative Diabetic Retinopathy (PDR) and diabetic macular edema (DME). Steroids seems to have a powerful effect on DME but also on VEGF inibition.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×